Related Experiment Video
Updated: Jun 24, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
Treatment Outcomes of Scleroderma With Janus Kinase Inhibitors: A Systematic Review
Hibo Rijal1, Naïla Bouadi2, Vincent Piguet3,4
1Queen's University School of Medicine, Kingston, ON, Canada.
Journal of Cutaneous Medicine and Surgery
|June 11, 2024
Abstract
No abstract available in PubMed .
Keywords:
Janus Kinase inhibitorsdiffuse cutaneous systemic sclerosislocalized cutaneous systemic sclerosismorpheasclerodermasystematic reviewsystemic sclerosistherapeutictreatmentMore Related Videos
Related Concept Videos
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421

